PharmiWeb.com - Global Pharma News & Resources
14-May-2019

Kancera's research will be highlighted at this year's largest conference on cardiovascular diseases

Kancera AB (Nasdaq First North: KAN) today announces that the European Society of Cardiology has selected Kancera's research for its "outstanding quality" which will result in an oral presentation as part of the session "Advances in Science - Emerging treatments in acute coronary syndromes" at the major conference ESC 2019 in September. The presentation will cover previously reported preclinical findings, which show that KAND567 has an anti-inflammatory effect and protects the heart at myocardial infarction and blood vessels at atherosclerosis.

“Our Fractalkine project breaks new ground in cardiac research. The fact that this year's largest scientific meeting in the cardiovascular field draws attention to our research is gratifying and strengthens our choice of indication, ”says Thomas Olin, CEO, Kancera AB.

The co-authors of this scientific work include researchers from the University of Newcastle, Karolinska Institutet, AstraZeneca and Kancera.

The presentation will be held at ESC 2019 in Paris on September 3rd.

About Kancera AB (publ)
Kancera develops drugs that counteract damage during acute and chronic inflammation. The Fractalkine blocker KAND567 is primarily developed to effectively and selectively reduce the inflammation of the heart and vessels following a heart attack and is expected to enter the clinical phase II study in 2019. Since scientific studies have shown elevated levels of fractalkine not only in heart attacks but also in inflammatory diseases and certain forms of cancer, there are several possible development opportunities for the fractalkine blockers KAND567 and KAND145. Kancera also develops preclinical drug projects against cancer aimed at stopping survival signals in the cancer cell and preventing the cancer cell's ability to be repaired. Kancera operates at Karolinska Institutet Science Park in Stockholm. The share is traded on Nasdaq First North. FNCA Sweden AB (tel. 08-528 00 399, info@fnca.se) is the company's Certified Adviser. MD PhD Charlotte Edenius, MD PhD Anders Gabrielsen, Professor Carl-Henrik Heldin and Professor Håkan Mellstedt are all scientific advisors and board members of Kancera AB.

For further information, contact:
Thomas Olin, CEO: +46-(0)735-20 40 01

Adress:
Kancera AB (publ)
Karolinska Institutet Science Park
Banvaktsvägen 22
SE 171 48 Solna

Editor Details

Last Updated: 16-May-2019